Category Archives: Inducement to Infringe

Horizon’s OB ‘913 claim 12 survives obviousness challenge (Pennsaid® for osteoarthritis)

HZNP Medicines LLC et al. v. Actavis Laboratories UT, Inc. Docket No. 2017-2149, -2152-53, -2202-3, -2206 PROST, NEWMAN, REYNA October 10, 2019 Brief Summary: DC findings of indefiniteness, no induced infringement, and no invalidity for obviousness regarding Horizon’s OB patents … Continue reading

Posted in Claim Construction, Generics / ANDA, Indefiniteness, Inducement to Infringe, Infringement, Obviousness, Uncategorized | Leave a comment

Grant of SJ of non-infringement reversed due to “genuine dispute of material fact on…whether the…software was capable of infringing uses”

NeuroGrafix, et al. v. Brainlab, Inc. et al. Docket No. 2018-2363 NEWMAN, O’MALLEY, TARANTO October 7, 2019 Non-precedential Brief Summary: Grant of SJ reversed due to “genuine dispute of material fact on…whether the…software was capable of infringing uses”. Summary: NeuroGrafix … Continue reading

Posted in Claim Construction, Inducement to Infringe, Infringement, Uncategorized | Leave a comment

DC grant of SJ of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”

Phigenix, Inc. v. Genetech, Inc. Docket No. 2017-2617, 2018-1042 REYNA, BRYSON, STOLL September 5, 2019 Non-Precedential Brief Summary: DC grant of SJ of no induced infringement after exclusion of Phigenix’s expert report affirmed (e.g., “[w]ithout its expert report, Phigenix’s direct … Continue reading

Posted in Inducement to Infringe, Infringement, Uncategorized | Leave a comment

DC grant of SJ to Genentech of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”

Phigenix, Inc. v. Genetech, Inc. Docket No. 2017-2617, 2018-1042 REYNA, BRYSON, STOLL September 5, 2019 Non-Precedential Brief Summary: DC grant of SJ of no induced infringement after exclusion of Phigenix’s expert report affirmed (e.g., “[w]ithout its expert report, Phigenix’s direct … Continue reading

Posted in Inducement to Infringe, Infringement, Uncategorized | Leave a comment

Omega Patents, LLC v. CalAmp Corp.

Docket No. 2018-1309 PROST, DYK, WALLACH April 8, 2019 Brief summary: DC decision finding infringement of ‘727 claim 1 affirmed; others reversed and remanded for state of mind analysis and to determine whether there were predicate acts of infringement; willfulness … Continue reading

Posted in Attorney's Fees, Claim Construction, Damages, Inducement to Infringe, Infringement, Willfullness | Leave a comment

Grunenthal Gmbh et al. v. Alkem Labs. Ltd., Hikma Pharm., Actavis et al.

Docket No. 2017-1153, -2048-50 REYNA, TARANTO, CHEN March 28, 2019 Brief summary: DC decisions of nonobviousness of Grunenthal’s polymorph claims, no induced or contributory infringement due to section viii carve-out, and specific utility of the claimed polymorph affirmed. Summary: Alkem … Continue reading

Posted in Anticipation (35 USC 102), Contributory Infringement, Generics / ANDA, Inducement to Infringe, Inherency, Obviousness, Utility | Leave a comment

Mark A. Barry v. Medtronic, Inc.

Docket No. 2017-2463 PROST, MOORE, TARANTO January 24, 2019 Brief summary: DC and jury conclusions of no invalidity and infringement affirmed (e.g., the invention was not in “public use” as the use was experimental, no § 102(b) on-sale bar, no … Continue reading

Posted in Anticipation (35 USC 102), Conception and Reduction to Practice, Experimental Use, Inducement to Infringe, Inequitable Conduct, Infringement, Preamble, Public Use | Tagged | Leave a comment

Enplas Display Device Corp. et al. v. Seoul Semiconductor Company, Ltd.

Docket Nos. 2016-2599 NEWMAN, HUGHES, STOLL Nov. 19, 2018 Brief summary: DC findings of no anticipation affirmed; damages award vacated (e.g., “damages calculated by applying a royalty rate to sales of non-accused lenses cannot support a jury’s verdict on damages”). … Continue reading

Posted in Anticipation (35 USC 102), Contributory Infringement, Damages, Inducement to Infringe, Royalties | Leave a comment

AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. et al.

Docket No. 2016-2475 MOORE, REYNA, TARANTO May 11, 2018 Brief summary: DC dismissal of AHF’s request for DJ for not relating to a current “substantial controversy” affirmed. Summary: AHF appealed DC dismissal of its request for a declaratory judgment (DJ) … Continue reading

Posted in Article III disputes, Inducement to Infringe | Leave a comment

Vanda Pharm. Inc. v. West-Ward Pharm. Int. Ltd. et al.

Docket No. 2016-2707, -2708 PROST, LOURIE, HUGHES April 13, 2018 Brief summary: DC finding of infringement of later-issued OB patent by amended ANDA, and that method of treatment claims are patentable under § 101 affirmed. Summary: WW appealed DC holding … Continue reading

Posted in Generics / ANDA, Inducement to Infringe, Infringement, Jurisdiction, Patentability, Written description | Leave a comment